We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

002241:SZSEGoertek Inc. Analysis

Data as of 2026-03-07 - not real-time

CN¥25.36

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Goertek Inc. (002241.SZ) is trading at ¥25.36, comfortably below its 20‑day SMA of ¥26.21 and the 50‑day SMA of ¥27.84. The 14‑day RSI sits at 37.4, indicating limited buying momentum but not yet oversold territory. A bearish MACD histogram (‑0.06) reinforces the short‑term downside bias. The stock is perched near a technical support level of ¥24.70, with resistance around ¥27.20. Volume has remained stable, while 30‑day price volatility is elevated at roughly 28%, suggesting price swings could be sizable. Market sentiment is bullish, as reflected by a fear‑greed index of 68.8 (“Greed”).
Fundamentally, revenue grew 4.4% YoY to ¥99.4 bn, yet margins remain thin (gross 11.9%, net 2.9%). The trailing PE of 30.2 is below the industry average of 36.2, but a discounted cash‑flow model values the company at only ¥8.02, implying the market price is materially overvalued. The balance sheet shows net cash of ¥0.88 bn and a debt‑to‑equity of 59%, a manageable leverage profile for a cash‑rich tech firm. Dividend yield stands at 1.58% with a payout ratio of 30%, supporting the view that the dividend is sustainable. Analyst consensus is a “Buy” with a median target of ¥35.8, indicating roughly 35% upside potential. Given the mixed technical weakness, overvaluation relative to DCF, and solid cash flow, we rate the stock as a medium‑term buy but advise caution on short‑term entries.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below key moving averages
  • Bearish MACD signal
  • Proximity to technical support

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Analyst consensus buy with 35% upside
  • Improving forward PE and EPS guidance
  • Solid cash position and sustainable dividend

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • DCF indicates significant overvaluation
  • Modest revenue growth and thin margins
  • Manageable leverage and net cash

Key Metrics & Analysis

Financial Health

Revenue Growth4.40%
Profit Margin2.92%
P/E Ratio30.2
ROE8.17%
ROA2.05%
Debt/Equity59.11
P/B Ratio2.5
Op. Cash FlowCN¥5.0B
Free Cash FlowCN¥1.7B
Industry P/E36.2

Technical Analysis

TrendNeutral
RSI37.4
SupportCN¥24.70
ResistanceCN¥27.20
MA 20CN¥26.21
MA 50CN¥27.84
MA 200CN¥27.68
MACDBearish
VolumeStable
Fear & Greed Index68.77

Valuation

Fair ValueCN¥8.02
Target PriceCN¥34.30
Upside/Downside35.25%
GradeOvervalued
TypeBlend
Dividend Yield1.58%

Risk Assessment

Beta0.49
Volatility27.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.